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II. Abstract 
Reactive oxygen species (ROS) have been specifically highlighted as instigators of aberrant 
pro-survival and proliferative signal transduction pathways in recent years. A possibility that 
ROS stimulates the Src-Protein Kinase B (PKB)-Glycogen Synthase Kinase (GSK)3-β 
pathway, a non-canonical pro-survival and anti-apoptotic pathway, was identified and 
investigated. Specifically, Human Oesophageal Squamous Cell Carcinoma (HOSCC) cells 
were exposed to oxidative conditions, Src inhibition, and a combination of the two to 
determine the role that Src plays in the phosphorylation of PKB and GSK3-β in terms of ROS 
stimulation. Oxidative conditions led to a significant increase in pSrc and pPKB in only one 
of the 5 HOSCC cell lines being studied; however the abundances of pGSK3-β increased 
significantly in two of these cells lines and decreased significantly in two of the others. This 
indicates that oxidative conditions lead to different downstream effects in the various 
HOSCC cell lines, which are most likely achieved via the activation of various pathways as a 
result of crosstalk. Src inhibition led to a decrease in pPKB levels across all HOSCC cell 
lines displaying detectable levels of pPKB, however the abundance of pGSK3-β increased in 
these cell lines, indicating again that other pathways are at play with respect to the activation 
of GSK3-β in HOSCC cells. This is due to the fact that GSK3-β is a downstream effector of 
PKB, and should thus decrease in abundance as pPKB does. Oxidative conditions coupled 
with Src inhibition resulted in an increase in the abundance of pPKB and pGSK3-β in four of 
the five HOSCC cell lines. These results indicate that Src inhibition under oxidative 
conditions may lead to cell survival and proliferation via the activation of pPKB, a pivotal 
pro-survival protein, and subsequent inactivation of pGSK3-β, a known pro-apoptotic 
protein. Thus, although more than one pathway is likely to be involved in the phosphorylation 
of PKB and GSK3-β in HOSCC in terms of ROS, it appears as though inactive Src in 
HOSCC cells undergoing oxidative stress could be used as a testable marker for HOSCC – a 
devastating disease affecting numerous South Africans.  
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1. Introduction 
 
1.1. Cell Signalling 
In order to maintain a state of homeostasis, it is essential for every cell to be able to monitor 
its environment and respond appropriately (Kültz, 2005). Monitoring and responding to the 
environment generally entails reacting to stimuli. Stimuli can originate from the external 
environment, neighbouring cells, or the cell itself (autocrine signalling). Stimuli, such as 
growth factors, hormones, and – of relatively new-found importance – reactive oxygen 
species are usually detected by receptor proteins on the cell surface (Son et al., 2011). The 
receptor proteins transfer the signal from the external environment into the cytoplasm by 
triggering a signal transduction cascade involving many proteins; usually kinases and 
phosphatases (Jans, 1994).  
Protein kinases are physiological catalysts, or enzymes, that facilitate the phosphorylation of 
their specific substrates (Walsh et al., 1971). Phosphate groups are negatively charged 
molecules that have the ability to bind to amino acids such as Serine, Threonine and Tyrosine 
(Taylor et al, 1995). Because phosphate groups are negatively charged, phosphorylation of a 
target molecule can change its structure and thus convert it into its active or inactive 
conformation (Westheimer, 1987). Protein phosphatases play the opposite role of 
dephosphorylating their substrates at specific sites (Chen et al., 1992), thus also changing the 
shape of the substrate and activating or inactivating it. In most cases, the kinase or 
phosphatase phosphorylates, or dephosphorylates, and activates or inactivates more than one 
protein, leading to the activation of more than one pathway (Jans, 1994). This phenomenon is 
known as cross-talk.  
Cross-talk is described as a complex interaction between cell signalling pathways, for 
example between the MAPK and PI3K/PKB pathway (Mendoza & Blenis, 2011). There are 
various points of cross-talk between these two pathways, for instance they can both be 
activated by the same receptor protein and they can cross-activate, and cross-inactivate, one 
another (Mendoza & Blenis, 2011). The fact that there are many examples of cross-talk 
between just two pathways emphasises the complexity of cross-talk, as the possibilities of 
cross-talk between all known pathways are seemingly endless. 
The aim of signal transduction pathways is ultimately to elicit a response from the cell. This 
is achieved by enabling specific proteins to enter the nucleus, where they can act as, or 
activate, transcription factors (Silver, 1991). Activation of transcription factors leads to the 
synthesis of proteins responsible for the desired response, which is mostly cell proliferation, 
survival or apoptosis (Silver, 1991). Thus, errors in cell signalling, no matter the origin, often 
result in the transformation of normal cells to cancerous cells (Thompson, 1995). 
It is therefore essential to better understand cell signalling and its involvement in cancer to 
more effectively treat this disease. This unfortunately becomes complicated due to the fact 
that different cell types behave differently. In fact, samples from the same type of tumour 
11 
 
acquired from different people may behave differently in terms of signalling. Many 
specimens of the same sub-type of cancer must therefore be analysed in order to identify the 
different types of signalling within the same type of cancer. This will help to identify targets 
for potential therapeutics.  
Analysing these signal transduction pathways includes pathway manipulation where stimuli 
and components of the pathway of interest must be investigated. For the purpose of this 
research, the stimulus being investigated was reactive oxygen species (ROS) and the pathway 
being manipulated was the Src/PKB/GSK3-β pathway. 
1.2. Reactive Oxygen Species in Cell Signalling 
Cell signalling begins with a stimulus (Kültz, 2005). These stimuli, such as hormones and 
growth factors, have long been studied with respect to diseases associated with cell 
signalling. However, ROS, a relatively new-found stimulus, has emerged as a signalling 
molecule of great importance in terms of cell signalling-related diseases such as cancer 
(Pelicano et al., 2004). 
Reactive oxygen species such as hydrogen peroxide (H2O2) are produced as by-products of 
cellular metabolism in aerobic organisms. These ROS play an essential role in signal 
transduction, where they act as stimuli and secondary messengers (Nishikawa, 2008). 
Although ROS are necessary for cellular function, high concentrations - which lead to 
oxidative stress – can damage or even kill cells by reacting with lipids, proteins and nucleic 
acids (Sosa et al., 2013).  
Slightly elevated levels of ROS can, however, have different effects on cells as various cell 
types have a range of capacities by which they respond to ROS. Because cancer cells tend to 
produce higher levels of ROS when compared to their non-transformed counter parts (Dang, 
2012), they have to adapt to an oxidative environment in order to survive. Indeed, cancer 
cells not only produce high levels of ROS; they tend to also accumulate ROS. They thus exist 
in a consistently oxidative environment (Grek & Tew, 2010).  
ROS tend to be particularly involved in the initiation and preservation of pathways involved 
in cell survival and proliferation (Dahan et al., 2009). The oxidative environment which 
cancer cells create, and exist in, is therefore conducive to the distinguishing trait of 
uncontrolled proliferation and prolonged survival. Thus, increased levels of ROS are thought 
to be one of the main mechanisms by which the cancerous phenotype of transformed cells is 
maintained (Gibellini et al., 2010). 
The involvement of ROS in cell signalling pathways in human oesophageal squamous cell 
carcinomas (HOSCC) are relatively unknown. Thus, HOSCC was used as the model for this 
investigation as squamous cell carcinomas are of particular interest in terms of ROS-related 
signalling. This is because Maehata et al. (2010) observed that ROS stimulate tumour 
progression as well as angiogenesis in head and neck squamous cell carcinomas. ROS have 
also been identified as key players in epithelial-mesenchymal transition (EMT) in skin 
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squamous cell carcinomas (Lam et al., 2013) and mammary epithelial cells (Cichon & 
Radisky, 2014).  
ROS are therefore important targets for cancer research, particularly in terms of squamous 
cell carcinomas, as they are highly involved in both the transformation and maintenance of 
the cancerous phenotype. Thus, in order to better understand the influence of ROS on cell 
signalling in HOSCC cells, it is essential to gain a superior understanding of the pathways 
triggered by ROS signalling.   
1.3. ROS-triggered Signalling 
The undeniable involvement of ROS in the stimulation of proliferation and survival pathways 
in cancer cells (Groeger et al., 2009) underscores the urgency to identify a component in a 
signal transduction pathway that is crucial to these processes. Intensive investigations have 
been undertaken over many years to characterise a pathway involved in proliferation and cell 
survival in terms of malignancy. This pathway is known as the mitogen-activated protein 
kinase (MAPK) pathway, or the Ras-Raf-MEK-ERK pathway. 
1.3.1. ROS signalling triggers the MAPK pathway 
In terms of oncogenesis, the MAPK pathway has often been identified as a component of the 
origin and/or maintenance of the transformed phenotype in many types of cancers (Son et al., 
2011). The MAPK pathway consists of a family of protein serine/threonine kinases that play 
a major role in transducing extracellular signals to the nucleus, stimulating cell growth and 
proliferation (Son et al., 2011). This pathway is canonically activated by the Epidermal 
Growth Factor Receptor (EGFR) (Wu et al., 1993), however it is also affected by ROS 
(McCubrey et al., 2006).  
Just below the surface of the cell, Ras proteins are activated via Receptor Tyrosine Kinases 
(RTKs) such as EGFR that have been stimulated by their ligands, or by ROS in a ligand-
independent manner (McCubrey et al., 2006). Ras proteins form part of the family of small 
Guanosinetriphosphatases (GTPases). Active Ras goes on to activate Raf in the canonical 
MAPK pathway, however Ras has other known downstream effectors such as 
Phosphoinositide-3-Kinase (PI3K) (Rajalingam et al., 2007) which will be discussed in 
section 1.3.3.  
Raf goes on to activate the MAPK/ERK Kinase (MEK), which leads to the activation of 
Extracellular Regulated Kinase (ERK) (McCubrey et al., 2006). ERK is associated with the 
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circumvention of apoptosis and the stimulation of proliferation (McCubrey et al., 2006). 
There are also receptor-independent ROS-mediated mechanisms whereby ERK becomes 
active (McCubrey et al., 2006), yet inhibition of ERK and other components of the MAPK 
pathway has little effect on tumours with hyper-activated Ras and EGFR proteins (Ishii et al., 
2013). This hints at the activation of other pro-survival and proliferative pathways by Ras and 
EGFR. 
Thus, although the MAPK pathway (and its association with ROS) is well known, it has 
provided little promise with respect to therapeutic intervention (Rajalingam et al., 2007). It is 
therefore essential to examine another, equally relevant pathway related to ROS signalling 
and cancer, such as the Protein Kinase B (PKB) pathway. 
1.3.2. The PKB pathway: a noteworthy contributor to transformation 
PKB, also known as Akt, is central to the activation of many proteins involved in pro-
survival and proliferative pathways as well as the inactivation of proteins involved in pro-
apoptotic pathways (see Figure 1.1). PKB becomes active in response to many stimuli such as 
growth factors and ROS, however, the canonical pathway by which it is activated is via 
receptor tyrosine kinases (RTKs) on the cell surface (Hemmings and Restuccia, 2012).  
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Figure 1.1 Multiple Signla Transduction Pathways Activated by PKB (Akt) 
PKB is central to the activation of multiple signal transduction pathways. These include pro-survival 
pathways, proliferative pathways and anti-apoptotic pathways. The activation of PKB thus 
presumably results in cell survival and proliferation. Its aberrant activation often results in the 
transformation of cells and the maintenance of the cancerous phenotype. Figure from Hemmings and 
Restuccia (2012). 
 
Growth factors bind to and activate these RTKs, which recruit Phosphoinositide-3-Kinase 
(PI3K) to the cell surface, resulting in its activation. PI3K is localised to the membrane by the 
RTK which leads to the subsequent activation of its 110 kDa catalytic subunit (Clerkin et al., 
2008). The catalytic subunit of PI3K then phosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2) to generate the secondary messenger, phosphatidylinositol 3,4,5-
triphosphate (PIP3). PIP3 recruits phosphoinositide-dependent kinase (PDK) 1, to the plasma 
membrane (Ziemba et al., 2013) where it partially activates the co-recruited PKB by 
phosphorylating it at Thr308. PKB becomes fully activated (pPKB) when phosphorylated at 
Ser473 by PDK 2 (see Figure 1.2) (Blanco-Aparicio et al., 2007).  
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The activation of PKB is negatively regulated by the protein tyrosine phosphatase Phosphate 
and Tensin Homolog (PTEN), which dephosphorylates PIP3 (see Figure 1.2), thus inhibiting 
the activation of PDK 1 (Hemmings and Restuccia, 2012). The inactivation of PTEN thus 
leads to an increase in the abundance of pPKB, which has been associated with enhanced cell 
survival, proliferation and invasion (Shukla et al., 2007).  Interestingly, H2O2, a reactive 
oxygen species, oxidises and inactivates PTEN and other protein tyrosine phosphatases 
(Leslie et al., 2003). The mechanism of activation of PKB by ROS will be discussed in 
section 1.3.4. 
 
 
Figure 1.2: Canonical Activation Pathway of PKB (Akt) 
PKB becomes canonically activated via the ligand-dependent activation of RTKs and the subsequent 
activation of PI3K. This leads to a signal transduction cascade that results in the phosphorylation of 
PKB at Thr308 by PDK1 and Ser473 by PDK2. This process is negatively regulated by PTEN, which 
inhibits the activation of PDK1 by dephosphorylating PIP3 to generate PIP2. Figure adapted from 
Hemmings and Restuccia (2012). 
Because pPKB plays a central role in the activation of many pathways involved in cell 
survival and proliferation, it is essential that the PKB pathway be studied with as equal an 
intensity as the MAPK pathway. This is especially true considering the lack of progress the 
MAPK pathway has produced in terms of therapeutic targets. 
1.3.3. Cross-talk between the MAPK and PKB pathways 
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As mentioned previously, active Ras has the ability to activate PI3K which will ultimately 
activate PKB. There are, however, other mechanisms by which the MAPK and PI3K/PKB 
pathways affect each other. Indeed, depending on the upstream signal, these pathways can 
cross-inhibit or cross-activate one another, as well as converge (Mendoza & Blenis, 2011). 
An example of the cross-inhibition between these pathways is the inactivation of PKB by 
MEK (Yu et al., 2002). Conversely, PKB negatively regulates Raf by phosphorylating sites 
that inhibit its activation (Guan et al., 2000). Thus, in untransformed cells, the MAPK and 
PI3K/PKB pathways regulate each other to mediate growth and proliferative signalling (See 
Figure 1.3). Therefore, when one pathway is inhibited, the other often becomes hyper-
activated, or, when one pathway is activated the other may become inactive. 
These pathways also cross-activate one another, where MAPK signalling can activate 
mammalian target of rapamycin complex 1 (mTORC1) – a downstream effector of pPKB. 
However, as this activation is PI3K and PKB independent (Mendoza & Blenis, 2011), this 
particular instance of cross-talk between the pathways is not of interest for the purpose of this 
research. The PI3K/PKB and MAPK pathway can also act in unison to phosphorylate 
downstream proteins involved in survival and proliferation of the cell (Mendoza & Blenis, 
2011). One such protein is the glycogen synthase kinase 3 β (GSK3- β), which will be 
discussed in section 1.3.5. 
 
Figure 1.3: Cross-inhibition between the PI3K/PKB and MAPK pathways 
Although both the MAPK and PI3K/PKB pathways may become activated by the same receptor 
tyrosine kinase (RTK), they often have inhibitory effects on each other to prevent hyper-activation of 
a mutual downstream target. Green arrows indicate activating phosphorylations, while red arrows 
indicate inhibition.  
 
1.3.4. ROS-dependent activation of PKB  
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As mentioned briefly in section 1.3.2, the activation of PKB in cells exposed to oxidative 
conditions has been found to be due PTEN oxidation and inactivation in various cell types 
(Leslie et al., 2003; Silva et al., 2008; Zhang et al., 2007). Previous laboratory data, however, 
indicate that this does not appear to be the case in HOSCC cells (Shaw, 2011). This implies 
that there may be a non-canonical mechanism by which PKB becomes activated in response 
to oxidative conditions in HOSCC. It is thus necessary to investigate alternative mechanisms 
by which PKB becomes active in the presence of ROS, other than via PTEN inactivation or 
Ras activation. This is due to the apparent irrelevance of PTEN inactivation via ROS in 
HOSCC cells, as well as the lack of a solution to carcinogenesis provided by MAPK pathway 
manipulation. The next candidate most likely to have a major influence on the PKB pathway 
at this level, in terms of ROS, is the non-receptor tyrosine kinase Src.  
Src is a proto-oncogene that forms part of the Src family kinases (SFKs), a family of 
Serine/Threonine kinases with conserved homology. These kinases have been implicated in 
cell signalling pathways involved in survival, proliferation, morphology, motility and 
invasion (Parsons and Parsons, 2004). Src is inactive when phosphorylated at Tyr527 and 
must be dephosphorylated at this site in order for activation to occur. Once Src has been 
dephosphorylated at Tyr527, it adopts an active, “open” conformation. This allows Tyr416 to 
become auto-phosphorylated, thus fully activating the protein (pY416 Src) (Giannoni et al., 
2005). The abundance of Src phosphorylated at Y416 increases when cells are exposed to 
exogenous H2O2 (Zhougang & Schnellmann, 2004). 
Active Src has many substrates such as adaptor molecules, cytoskeletal proteins, other 
kinases, as well as nucleotide-binding proteins (Parsons and Parsons, 2004). These substrates 
include EGFR, Ras and PI3K (Arcaro et al., 2007), all of which play a role in the 
phosphorylation of PKB. pSrc itself may also interact directly with PKB (see Figure 1.4), 
phosphorylating it at numerous tyrosine residues which allows for the activating 
phosphorylation at Thr308 by PDK1 (Vojtechová et al., 2008). It thus appears that pSrc may 
play a major role in the activation of PKB via various pathways, all of which can be activated 
by ROS. In addition to this, there is a positive correlation between the abundance of pY416 
Src and invasiveness in HOSCC cells (Chen et al., 2010). 
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Figure 1.4: Proposed Mechanism of PKB Activation by ROS-induced Src Activation 
Sub-lethal levels of ROS lead to an increase in the abundance of active (phosphorylated Tyr416) Src. 
It has been found that H2O2 stimulates the activation of PKB. This activation may be mediated by Src, 
which plays a role in the activation of EGFR, Ras as well as PI3K. Green arrows represent activating 
phosphorylations, purple arrows represent activating phosphorylations by Src. 
 
Examining Src, and not Ras or PI3K individually, is essential, as Penuel and Martin (1999) 
found that inhibition of the individual pathways in chicken embryo fibroblasts did not block 
transformation by v-Src. In contrast, simultaneous inhibition of these pathways essentially 
prevented transformation. This indicates that both pathways are involved in the 
transformation activities of Src. It is therefore imperative to investigate the activation of Src 
in response to oxidative conditions in HOSCC cells. This will determine whether the alternate 
pathway by which PKB becomes phosphorylated in response to oxidative conditions is, in 
fact, related to the abundance of pSrc within the cell. 
 
1.3.5. ROS signalling and PKB inactivate GSK3-β 
 
Although the activation of PKB points to increased cell survival and proliferation, as well as 
a decline in apoptosis, it is not enough to assume that this is the case. Thus, a downstream 
effector of pPKB must also be monitored in response to pathway stimulation and 
manipulation. 
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Glycogen Synthase Kinase 3-β (GSK3-β) is a Serine/Threonine kinase involved in pro-
apoptotic signalling (Yoshino, 2015), where it degrades the pro-survival protein β-catenin 
and cell cycle progression-related Cyclin D1 when active (Hardt & Sadoshima, 2002). A lack 
of these proteins, due to active GSK3-β, thus presumably results in a lower rate of cell 
survival and proliferation. Indeed, active GSK3-β has been associated with apoptosis, while 
inactive GSK3-β phosphorylated at Ser9 (pGSK3-β) is associated with cell survival 
(Paweletz et al., 2001). It has been long known that GSK3-β is inactivated by PKB when it 
becomes phosphorylated on the Ser9 residue (Cross et al., 1995). An increase in 
phosphorylation of GSK3- β on the Ser9 residue is thus associated with an increase in pPKB 
abundance.  
 
GSK3-β has recently been found to play a role in the reaction of the cell to oxidative stress, 
where it becomes phosphorylated at the “inactivating” Ser9 residue in response to oxidative 
conditions (Feng et al., 2013). However, although this phosphorylation is assumed to be 
linked to PKB, little is known about the mechanism of the phosphorylation of GSK3-β in 
response to ROS stimulation. Thus, this study will also seek to discover whether the 
inactivation of GSK3-β in response to ROS is pPKB and/or pSrc related. 
 
GSK3- β in particular is of interest to this study because of its contribution to tumourigenicity 
in squamous cell carcinomas such as that of the cutaneous (Ma et al., 2007). Thus, it can be 
assumed that GSK3-β will play a similar role in the squamous cells of oesophageal 
carcinomas. 
 
1.4. Oesophageal Squamous Cell Carcinoma 
 
Oesophageal cancer is the 8th most common cancer in the world and causes the 6th most 
cancer-related deaths (Ferlay et al., 2013). It is thus associated with an extremely poor 
prognosis with a mortality to incidence ratio of 0.88 (Ferlay et al., 2013). It is, however, one 
of the least studied subtypes of cancer. It is for this reason that HOSCC cells were used as a 
model for this investigation. 
Squamous cells in particular, and not adenocarcinomas, were examined because HOSCC 
mainly affects residents of developing countries such as South Africa, where black males are 
highly susceptible. Approximately 6% of South African males are affected by this disease 
(Ferlay et al., 2013). It is thus essential that this type of cancer be understood in order to 
attempt to better treat this disease that affects so many South Africans.    
Previous laboratory data indicate that PKB becomes activated in HOSCC cells in the 
presence of exogenous H2O2. This process does not, however, appear to occur due to 
inactivation of protein tyrosine phosphatases or EGFR stimulation (Shaw, 2011). It is 
therefore of interest to examine the possibility that the activation of PKB by H2O2 in HOSCC 
cells is mediated by Src. Src is particularly relevant because a decrease in Srcasm (Src-
activating and signalling molecule), a molecule that inhibits Src activity, was observed in 
Chinese HOSCC cells (Qi et al., 2010). This indicates that the activity of Src may be 
20 
 
increased in HOSCC cells, possibly leading to increased levels of pPKB and pGSK3-β, and 
thus hyper-proliferation and extended cell survival. 
It is thus essential that the relationship between ROS, Src, and the phosphorylation status of 
PKB and GSK3-β be examined. This investigation was therefore performed in an attempt to 
better understand and perhaps identify a target for potential treatments of oesophageal 
squamous cell carcinomas – a devastating tumour that affects numerous South Africans. 
1.5. Aim and Objectives 
The connection between elevated levels of pSrc and squamous cell carcinomas, as well as its 
involvement in the activation of PKB and GSK3-β, has made it an interesting target for 
research in terms of HOSCC. Not only Src itself, but also pPKB and pGSK3-β, have been 
implicated in the formation of many tumours, including squamous cell carcinomas. These 
particular proteins of interest have all been recorded as being affected by reactive oxygen 
species (ROS). Thus, the aim of this investigation was to determine the role of Src in the 
phosphorylation of PKB and GSK3-β under oxidative conditions in HOSCC, in which the 
role of ROS and the Src-PKB pathway is relatively unknown. 
The objectives were as follows: 
 To determine the impact of an oxidative environment on the abundance of pSrc, 
pPKB and pGSK3-β in HOSCC cells. This was performed in order to establish 
whether Src plays a role in the phosphorylation of PKB in response to ROS 
stimulation. The effectiveness of the PKB activation was determined by examining 
the abundance of pGSK3-β, a downstream effector of pPKB. 
 To determine the role of Src in the phosphorylation of PKB and pGSK3-β by 
inhibiting Src. The abundances of pPKB and pGSK3-β were investigated in response 
to Src inhibition to identify the role of Src in their phosphorylation status under 
standard tissue culture conditions. 
 To determine the role of Src in the phosphorylation of PKB and pGSK3-β in response 
to ROS stimulation. The abundance of pPKB and pGSK3-β were investigated in 
response to Src inhibition in an oxidative environment. This was performed to 
determine the role of Src in the phosphorylation of PKB and GSK3-β in cells 
undergoing oxidative stress. 
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2. Methods and Materials 
 
2.1. Tissue Culture 
Five HOSCC cell lines derived from moderately differentiated and metastatic tumours, as 
well as two control cell lines, were obtained from the School of Molecular and Cell Biology, 
University of the Witwatersrand, Johannesburg. The HOSCC cell lines included the Wits 
Human Carcinoma of the Oesophagus WHCO1, WHCO3, WHCO5 and WHCO6 cell lines 
(Veale and Thornley, 1989) as well as the SNO cell line (Bey et al., 1976). H1299 non-small 
cell lung carcinoma cells (Giaccone et al., 1992) were used as a positive control cell line for 
pPKB and pGSK3-β detection. This is due to the high levels of pPKB and pGSK3- β present 
in H1299 cells as a result of a methylated PTEN promoter (Soria et al., 2002). A431 
epidermoid carcinoma cells (Giard et al., 1973) were used as a positive control for the 
detection of pSrc, and as a comparative epithelial cell line with high EGFR expression 
(Shimizu et al., 1984). These control cell lines were also used due to “normal” human 
oesophageal squamous cells being unavailable for comparison (Jankowski et al., 1995).  
All cell lines were cultured as a monolayer in Dulbecco’s Modified Eagle’s Medium 
(DMEM)/Ham’s F12 (3:1) (see appendix A 1.1 – 1.3) supplemented with 10% Foetal Calf 
Serum (FCS) (Highveld Biological) and were maintained in a humidified 37 oC incubator 
with an established atmosphere of 5% CO2. These conditions mimic physiological conditions. 
Cells were sub-cultured upon reaching 80% confluency to avoid potential changes in 
signalling due to contact inhibition. This was performed by discarding the medium, rinsing 
the cells with sterilized 1 x Phosphate Buffer Saline (PBS) (see appendix A 1.4) and adding 
Trypsin (Gibco BRL)/ Ethylene Diaminetetra Acetic Acid (EDTA) (BDH Laboratory 
reagents) (see appendix A 1.5). Cells were incubated in Trypsin/EDTA at 37 oC for 5 minutes 
to facilitate detachment. A fraction of the detached cell-Trypsin/EDTA mixture was 
transferred to a new dish, where medium containing 10% FCS was then added to the cells. 
Tissue culture then continued as stated above. All studies were routinely performed on cells 
approaching 80% confluency due to there being no detectable contact inhibition at this 
density. 
2.1.1. ROS stimulation through exposure to Hydrogen peroxide (H2O2) 
Cells approaching a confluency of 80 % were exposed to oxidative conditions. The cells were 
rinsed twice with 1 x PBS. They were then incubated in medium supplemented with 5% FCS 
containing 1 mM hydrogen peroxide (Unilab®/SAARCHEM (Pty) Ltd) for 1 hour. 
2.1.2. Src inhibition  
Cells approaching 80 % confluency were rinsed twice with 1 x PBS. They were then 
incubated for 1 hour in medium supplemented with 5 % FCS to which 10 nM KX2-391 (KX-
01) (Selleckchem) in dimethylsulphoxide (DMSO) was added.  
2.1.3. Src inhibition under oxidative conditions 
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Cells approaching 80 % confluency were rinsed twice with 1 x PBS. They were then 
incubated for 1 hour in medium supplemented with 5 % FCS containing 1 mM H2O2, to 
which 10 nM KX-01 in DMSO was added. 
 
2.2. Whole Cell Protein Extraction 
In order to extract all protein from the cells, untreated cells at 80 % confluency or cells 
treated as detailed above were rinsed twice with 1 x PBS. The cells were then rinsed with 1 x 
PBS containing a protease inhibitor; 1mM phenylmethane sulfonyl fluoride (PMSF) in 
methanol, as well as phosphatase inhibitors; 5 mM Sodium Fluoride (NaF) and 10 mM 
Sodium Orthovanadate (Na3VO4). This was to avoid protein degradation and to maintain the 
phosphorylation status of the proteins. Cells were scraped off the dish into the PBS 
containing protease and phosphatase inhibitors. This solution was transferred to a 1.5 ml 
Eppendorf microfuge tube and centrifuged at 12 000 RPM for 30 seconds. The supernatant 
was discarded and the cells were resuspended in 2x Laemmli lysis buffer (Laemmli, 1970) 
(see appendix A 2.1). The lysate was boiled for 5 minutes and centrifuged at 4 oC for 15 
minutes at 12 000 RPM. 
2.3. Protein Determination 
The protein content in each whole cell protein extraction was determined via a Bradford 
assay with the modifications proposed by Bramhall et al. (1969) to reduce the effects of SDS 
on the measurement. Whatmann filter paper was rinsed in dH2O for 20 minutes and was then 
dehydrated by rinsing it in 95% ethanol, 100% ethanol and 100% acetone for 5 minutes each. 
This was performed to reduce any loose fibres that would otherwise come off in later steps 
and possibly lead to the rinsing off of stain. The filter paper was left to dry. Volumes of 1, 3, 
6, 12, 16, and 20 µl of 1 mg/ml Bovine Serum Albumin (BSA) in 2x Laemmli lysis buffer, as 
well as a known volume of the whole cell protein extracts, were dotted onto the filter paper 
and left to dry. The protein content was then fixed onto the filter paper by incubation in 7.5 % 
trichloracetic acid (TCA) for 45 min. The filter paper was rinsed with Coomassie Brilliant 
Blue stain (see appendix A 3.1) for 5 minutes, after which it was stained for 1 hour. The filter 
paper was then destained (see appendix A 3.2) for 1 hour, leaving stained protein-dye spots. 
The spots were placed into separate test tubes, into which 5 ml of elution solution (see 
appendix A 3.3) was added, and left overnight in the dark. The absorbance of each sample 
was then determined using an Abotta SV-1100 spectrophotometer at a wavelength of 595 nm. 
The BSA readings were used to create a standard curve (see appendix B Figure B1), to which 
the readings of the protein extracts were compared to obtain the concentration of protein 
present in each respective sample.  
 
2.4. SDS PAGE and Western Immunoblotting 
The protein extracts prepared as described in 2.2 were separated via a discontinuous Sodium 
Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS PAGE) prepared according to 
Laemmli (1970) (see appendix A 4.1 and 4.2). Equal amounts of protein were loaded onto the 
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gel. Equal loading was confirmed later by analysing β-actin as a loading control. The proteins 
were resolved according to weight by applying a constant current of 21 mA using the Mighty 
Small TM Electrophoresis Unit, which was filled with running buffer (see appendix A 4.3). 
Resolved proteins were visualised (see appendix B Figure B2) by staining the gel with 
Coomassie Brilliant Blue (see appendix A 3.1) and destaining (see appendix A 4.4).  
Western Immunoblotting was performed as described by Towbin et al. (1979). Protein from 
unstained gels was transferred onto a nitrocellulose membrane (Nitrobind, MSI USA) by 
applying a current of 400 mA for 2 hours using a BioRad Trans-Blot TM filled with Transfer 
Buffer (see appendix A 5.1). The nitrocellulose membrane was rinsed with Tris Buffer Saline 
(TBS) (see appendix A 5.2). Non-specific binding sites were blocked by incubating the 
membrane in a blocking solution (see appendix A 5.3) at room temperature for 1 hour. The 
membrane was rinsed three times in TBS with 0.1 % Tween-20 (TBS-T) for 5 minutes and 
then incubated with the appropriate primary antibody (see appendix B table B1) at 4 oC 
overnight. The membrane was then rinsed three times in TBS-T for 5 minutes per rinse to 
eliminate any unbound antibody. The membrane was thereafter incubated in the appropriate 
dilution of horse radish peroxidase (HRP)-linked secondary antibody (see appendix B table 
B1) for 1 hour. Unbound antibody was eliminated once more by rinsing the membrane in 
TBS-T three times for 5 minutes per rinse. The detergent was then removed by rinsing the 
membrane in TBS (with no Tween-20) for 5 minutes. This was followed by a 5 minute 
incubation in the dark in a 1:1 ratio of luminol and peroxide (SuperSignal®, West Pico). The 
reaction was then contained by sealing the membrane in clear cling wrap (Versafilm®), 
which was exposed to CL-XPosureTM X-Ray film (Pierce) for 10 minutes in the dark. The X-
Ray film was immediately submerged in Developer (see appendix A 5.4), rinsed in water, 
submerged in Fixer (see appendix A 5.5) and again rinsed in water. 
2.5. Semi-Quantification of Western Blots 
The intensities of the visible bands present on the X-Ray film subsequent to Western Blotting 
are indicative of the abundance of a particular protein within the specific protein extract. 
Those bands were digitalised with a Hewlett Packard ScanJet G3110 desktop scanner and 
semi-quantified using Matlab Generator Densitometry Programme. Densitometry was 
standardised between different Western blots generated from extracts from the same cell line 
by dividing by the untreated control, which is represented as a relative percentage to the 
standard. The standard in this case was the intensity of the particular protein being examined 
in a whole cell extract from an untreated control cell line (H1299 for pPKB and pGSK3-β 
and A431 for pSrc). 
 
2.6. Statistical Analysis 
Statistical significance was determined by means of Student’s T-test, where a p-value of < 
0.05 indicates statistical significance. Error bars represent the standard error mean (SEM) of 
the biological replicates performed. 
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3. Results 
 
3.1. HOSCC cells express differential levels of pSrc, pPKB and pGSK3-β 
To detect the relative abundances of pSrc, pPKB, pGSK3-β and Actin, the whole cell 
protein contents extracted from untreated HOSCC and control cell lines, grown to 80 % 
confluency under standard conditions, were separated by SDS PAGE and underwent 
immunoblotting (as described in the methods and materials section 2.4). Unless otherwise 
stated, pGSK-β indicates the inactivating phosphorylation at the Ser9 residue.  
It should be noted that the changes in the phosphorylation status of proteins in response to 
stimuli is at a ρM level. Thus, detecting these small changes can be challenging. 
Therefore, a seemingly small and insignificant change in a phospho-site may have an 
impact on the cell in terms of signalling.    
Detecting these proteins in the untreated cells under standard tissue culture conditions 
served to confirm the presence or absence of the specific phospho-sites on the proteins of 
interest. The inclusion of the Western blot (See section 2.4) detecting Actin serves to 
demonstrate accurate loading of equal amounts of protein, as cytoskeletal protein 
expression remains unchanged across different cell lines (See Figure 3.1 D). The cell 
lines A431 and H1299 were used as comparative controls for pSrc, and pPKB and 
pGSK3-β respectively as they contain high levels of these phospho-proteins. This was 
necessary due to the unavailability of untransformed oesophageal squamous cells to be 
used as a comparison. 
All the HOSCC cell lines as well as the A431 control cell line, but not H1299 cells, 
expressed detectable levels of pSrc (See Figures 3.1 A). The untreated WHCO3 cell line 
did not express detectable levels of pPKB (See Figures 3.1 B), while the SNO cells did 
not display detectable levels of pGSK3-β (See Figures 3.1 C). Performing densitometry 
on these Western blots allowed for the semi-quantification of the intensity of the bands 
present on the blots (See Figure 3.2). The densitometric values confirmed that there are 
indeed differences in the amounts of the proteins phosphorylated at specific sites across 
the different cell lines. 
 
 
 
 
 
25 
 
 
  
  
  
 
Figure53.1: Differential Abundance of pSrc, pPKB and pGSK3-β in HOSCC and control cells 
The relative abundances of A) pSrc, B) pPKB, C) pGSK3- β and D) Actin across the 5 untreated 
HOSCC cell lines (WHCO1, WHCO3, WHCO5, WHCO6 and SNO) as well as the untreated A431 
and H1299 control cell lines detected by Western Blotting. Actin (D) was used as a control to ensure 
that loading was accurate and of equal amounts. 
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 Representation of the mean intensities of the bands present on Western blots in figures 3.1. A) 
depicts the mean densitometric values obtained from Western blots detecting pSrc in the untreated 
cell lines, while B) and C) represent those on the Western blots detecting pPKB and pGSK3-β 
respectively. Error bars represent the standard error mean (SEM) of the replicates. 
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Figure63.2: Different abundances pSrc, pPKB and pGSK3-β in HOSCC and control cell lines 
reflected semi-quantitatively (n=3). 
0
20
40
60
80
100
120
140
160
WHCO1 WHCO3 WHCO5 WHCO6 SNO A431 H1299
Ex
p
re
ss
io
n
 R
el
at
iv
e 
to
 S
ta
n
d
ar
d
pSrcA
B 
C 
27 
 
3.2. HOSCC cells respond dissimilarly to ROS stimulation 
The effect of ROS stimulation on the Src/PKB/GSK3- β pathway was analysed to determine 
whether oxidative conditions have an effect on the phosphorylation status of these proteins, 
and thus presumably cell survival, proliferation and ultimately carcinogenesis. This was 
performed by exposing HOSCC and control cells to 1 mM H2O2 for 1 hour. This particular 
concentration of H2O2 was used because the addition of micromillimolar levels of H2O2 has 
been found to be more effective at causing DNA lesions than millimolar concentrations. This 
could have a profound impact on the results (Nakamura, 2003). High levels of H2O2 have 
been found to be lethal to mammalian cells, whereas 1 mM has been used frequently to 
induce oxidative stress in cells (Janero, 1993; Kobayashi, 2005; Miguel, 2009) and has 
previously been used to induce oxidative stress in HOSCC cells in our laboratory (Shaw, 
2011). H2O2 was also used as the representative ROS because Forman et al. (2010) found 
that, of all the ROS, H2O2 satisfies the requirements of being a secondary messenger best. 
The cells were exposed to oxidative conditions for 1 hour because a titration performed 
previously determined that the cells are most responsive in terms of changes in 
phosphorylation after 1 hour. The oxidation of proteins is also thought to be reversible. Thus, 
allowing the cells to remain in an oxidative environment for too long risks missing the full 
effect of the oxidative conditions on the cells. There is also a risk of the antioxidants within 
the cells neutralising the ROS if the treatment is applied for too long. 
The densitometric analysis of biological replicates depicting the response of HOSCC and 
control cells to ROS stimulation are displayed as bar graphs below (see Figure 3.3). The bars 
represent the mean change in expression relative to the untreated control, while the error bars 
represent the standard error mean (SEM) of the replicates. An asterix above the bar indicates 
that the change in phosphorylation of a signalling intermediate is statistically significant, with 
a p-value less than 0.05.  
The abundance of pSrc in all cells lines was calculated relative to the abundance in A431 
cells, while pPKB and pGSK3-β levels were calculated relative to the abundance in H1299 
cells. These cell lines were thus used as loading controls for the respective proteins, allowing 
for the comparison of Western blots performed separately by controlling for day-to-day 
variation. This control for variation was practiced over all experiments performed. 
Although the conditions under which the cells were cultured were attempted to be kept as 
standard as possible, some variation (displayed as error bars) did occur. Because ROS levels 
can potentially be altered by stress, small differences in conditions can result in seemingly 
large variations in the abundance of sensitive phosphorylation sites. This is particularly true 
of proteins more sensitive to oxidative conditions.  
With the exception of WHCO6 cells which responded with a significant increase in the 
abundance of pSrc, all HOSCC and control cell lines displayed unchanged levels of pSrc in 
response to ROS stimulation (See Figure 3.3). ROS stimulation appeared to increase the 
abundance of pPKB in all cells lines other than SNO. However, due to variation, the only 
increase that can be said to be significant was again in the WHCO6 cell line.  
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Interestingly, the abundance of pGSK3-β decreased significantly in WHCO6 and WHCO3 
cells in response to ROS stimulation. WHCO1 and SNO cells responded to ROS stimulation 
with a significant increase in pGSK3-β. 
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Figure73.3: Changes in the abundances of pSrc, pPKB and pGSK3-β in HOSCC and control 
cell lines responding to ROS stimulation (n = 3). 
Representation of the mean changes in intensities (compared to untreated controls) obtained from 
biological replicates of HOSCC and control cells stimulated with ROS (1 mM H2O2 for 1 hour). Semi 
quantitative intensities originate from densitometric analysis of Western blots detecting A) pSrc, B) 
pPKB and C) pGSK3-β in the above-mentioned cells. Error bars represent the SEM of the replicates, 
while an asterix represents statistical significance (p < 0.05). See Table B2-4 for means, SEMs and p-
values. 
 
3.3. pPKB decreases, while pGSK3-β increases, in response to Src inhibition 
The experiments involving ROS stimulation indicate that oxidative conditions do not have an 
effect on pSrc levels in all HOSCC cell lines besides WHCO6 (See Figure 3.3A). They also 
indicate that oxidative stress may lead to an increase the abundance of pPKB, however this 
increase cannot be said to be significant in most cell lines (See Figure 3.3B), and had varying 
effects on the abundance of pGSK3-β (See Figure 3.3C). The effect of Src on these signalling 
intermediates was thus determined under standard tissue culture conditions – in the absence 
of ROS – in order to establish the relationship between pSrc and the activation status of PKB 
and GSK3-β. This was achieved by inhibiting Src with 10 nM KX-01, a specific inhibitor 
that targets the substrate pocket of Src. This concentration is consistent with the IC50 values 
(9 – 60 nM) provided by the distributers.  
Because of the nature of this inhibitor, the abundance of pSrc was not expected to change in 
response to being treated with KX-01 (See Figure 3.4 A). This is because KX-01 binds to the 
substrate-binding pocket but does not prevent the protein from being phosphorylated. In fact, 
in order for the inhibitor to work, Src must be phosphorylated at Y416 so that it is in its 
“open” conformation which allows for KX-01 to bind to the active site. The downstream 
signalling intermediates affected by Src should, however, be altered in response to the 
inhibition of Src.  
-100
-50
0
50
100
150
WHCO1 WHCO3 WHCO5 WHCO6 SNO A431 H1299
Ex
p
re
ss
io
n
 r
el
at
iv
e 
to
 u
n
tr
ea
te
d
 c
o
n
tr
o
l
pGSK3-β
*
*
*
*
C
30 
 
The changes in the abundance of phosphates on the sensitive phosphorylation sites of the 
proteins of interest are again displayed as a mean of biological replicates performed. 
Inhibition of Src resulted in a significant decrease in the abundance of pPKB in the WHOC1, 
WHCO5 and WHCO6 cell lines. The levels of pPKB in the SNO and A431 cells remained 
mostly unchanged in response to Src inhibition, while interestingly the H1299 cell line 
displayed an increase, albeit insignificant, despite displaying undetectable levels of pSrc (See 
Figure 3.4 B).  
Although the levels of pPKB generally decreased in response to Src inhibition, the significant 
changes in pGSK3-β are represented as increases in WHCO5, SNO and H1299 cells. The 
levels of pGSK3-β decreased significantly in WHCO3 cells despite them containing 
undetectable levels of pPKB, whereas the levels in WHCO1, WHCO6 and A431 cell lines 
appear to be unchanged (See Figure 3.4 C). 
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Changes in the abundances (compared to untreated controls) of A) pSrc, B) pPKB and C) pGSK3-β in 
HOSCC and control cell lines responding to Src inhibition (10 nM KX-01 for 1 hour). Bars of the 
graphs represent the mean intensities of Western blots detecting the appropriate proteins in biological 
replicates, while error bars represent the SEM. An asterix indicates statistical significance (p > 0.05). 
See Table B5-7 for means, SEMs and p-values. 
 
3.4. Src inhibition under oxidative conditions increases the abundances of both pPKB and 
pGSK3-β 
Both oxidative stress as well as Src inhibition had an effect on the levels of pGSK3-β and 
pPKB (although less notably in terms of oxidative stress). The role of Src in the activation of 
PKB and inactivation of GSK3-β under conditions of oxidative stress thus needed to be 
determined in order to better understand the effects of ROS on signalling intermediates 
implicated in carcinogenesis. This was achieved by stimulating the cells with ROS, while 
simultaneously inhibiting Src. 
A combination of Src inhibition and oxidative stress did not have a dramatic effect on most 
cells with respect to pSrc abundance. There was, however, a major and significant increase in 
pSrc abundance in WHCO6 cells and a less noteworthy but significant decrease in WHCO5 
cells (See Figure 3.5 A). These results highlight the fact that the Src inhibitor does not have 
an effect on the phosphorylation of Src itself, as the resultant increase in pSrc in WHCO6 
cells is highly similar to that of ROS stimulation alone. The small but significant decrease in 
pSrc abundance in WHCO5 cells indicates that the decrease in response to oxidative 
conditions alone may have been significant had the results been refined.  
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Figure83.4: Variations in the abundances of pSrc, pPKB and pGSK3-β in HOSCC and control 
cell lines responding to Src inhibition (n = 3). 
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All cell lines with detectable levels of pPKB responded to Src inhibition coupled with ROS 
stimulation with an increase in the abundance of pPKB (See Figure 3.5 B). These increases 
were significant in the WHCO5 and SNO cell lines. Other than WHCO3 cells which 
displayed an insignificant decrease, the abundance of pGSK3-β in the cells increased in 
response to a combination of ROS stimulation and Src inhibition (See Figure 3.5 C). The 
increases were significant in WHCO5, WHCO6, A431 and H1299 cells. 
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Figure93.5: Changes in Abundance of pSrc, pPKB and pGSK3-β in HOSCC and control cells 
responding to Src inhibition under oxidative conditions (n = 3). 
Changes in abundance of A) pSrc, B) pPKB and C) pGSK3-β from the untreated controls depicted as 
mean densitometric intensities. Results were obtained from Western blots performed on biological 
replicates of HOSCC and control cell lines responding to Src inhibition under oxidative conditions. 
These intensities are semi-quantitative representations of the bands present on the Western blots. 
Error bars represent the SEM of the replicates and an asterix symbolises statistical significance (p > 
0.05). See Table B8-10 for means, SEMs and p-values.   
  
4. Discussion 
The role of ROS as a cellular stressor has received a great deal of attention in recent years. 
An increase in ROS at sub-lethal doses may induce several cellular processes that have an 
influence on critical events such as cell survival and proliferation. The possibility that ROS 
stimulation of the Src-PKB-GSK3-β pathway has a significant input in this regard was 
investigated. Specifically, HOSCC cells were exposed to oxidative conditions, Src inhibition, 
and a combination of the two to determine the possible role played by Src in the 
phosphorylation of PKB and GSK3-β in terms of ROS stimulation.  It is imperative that 
detailed knowledge of these signalling pathways, and their aberrant counterparts, in response 
to critical stressors is acquired. This is necessary in order to obtain superior knowledge of the 
signal transduction pathways that enable the prolonged survival and hyper proliferation of 
cells. Moreover, such information is crucial if a testable marker for HOSCC is to be 
identified 
4.1. ROS stimulation affects HOSCC cells differentially in terms of pGSK3-β 
ROS stimulation did not have a significant effect on the abundance of pSrc and pPKB in the 
HOSCC and control cell lines other than WHCO6, which displayed a significant increase in 
both intermediates. Despite this, the levels of pGSK3-β increased insignificantly in WHCO5, 
significantly in WHCO1 and SNO, and decreased significantly in WHCO3 and WHCO6 cell 
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lines in response to ROS stimulation. The levels appeared to be unchanged in the A431 and 
H1299 control cell lines. 
The behaviour of the signalling intermediates in WHCO6 cells in response to oxidative stress 
indicates that ROS activate Src, which in turn activates PKB. The decrease in the inhibitory 
phosphorylation of GSK3-β is however contradictory to the “pro-survival” responses in the 
above mentioned intermediates, as it is well known that pPKB phosphorylates GSK3- β at the 
Ser 9 residue to avoid apoptosis (Cross et al., 1995). 
This decrease in the abundance of GSKS3-β on the Ser 9 residue may be due to the activation 
of the SFK Fyn. As with Src, Fyn becomes activated upon stimulation with H2O2 (Frossi et 
al., 2007). However, unlike Src, Fyn has been reported to activate GSK3-β, and therefore 
presumably decrease the phosphorylation on Ser 9 (Medina & Wandosell, 2011). Thus, 
WHCO6 cells may contain higher abundances of Fyn than the other HOSCC cell lines, 
however it is almost impossible to determine whether this is true as Src and Fyn have the 
same molecular mass.  
ROS stimulate more than one pathway corresponding to PKB and GSK3-β. Thus, despite the 
lack of response by pSrc and pPKB, there was an increase in the abundance of pGSK3-β in 
WHCO1, WHCO5 and SNO cells responding to oxidative conditions. This increase could be 
due to the MAPK pathway. The MAPK pathway has been instigated in the phosphorylation 
of both PKB and GSK3-β. However, the MAPK pathway also has a negative regulatory 
effect on the activation status of PKB (Yu et al., 2002), as mentioned in section 1.3.3. ERK, a 
member of the MAPK pathway, is known to regulate the PKB pathway tightly by 
inactivating PKB when the pathway appears to be signalling too strongly (Hayashi et al., 
2008). Thus, by activating the MAPK pathway, the cell may essentially be by-passing the 
Src-PKB pathway to phosphorylate GSK3-β (See Figure 4.1). In addition to this, pPKB 
inactivates Ras (Mendoza & Blenis, 2011). Thus, by inactivating PKB, the MAPK pathway 
may be further activating itself and therefore phosphorylating GSK3-β at the Ser 9 residue 
independently of Src and PKB. 
The fact that the levels of pPKB did not decrease may also implicate yet another pathway that 
is activated via ROS. The Wnt pathway, although less documented, is also known to become 
activated by oxidative conditions (Korswagen, 2006). The main role of the Wnt pathway is to 
increase survival by allowing for the accumulation of β-catenin in the cell. It does so by 
phosphorylating GSK3-β at the ser 9 residue, as active GSK3-β targets β-catenin for 
destruction (Hardt & Sadoshima, 2002). There is also evidence of crosstalk between the Wnt 
and PKB pathway, where Wnt has been found to activate PKB (Fukumoto et al., 2001). 
Thus, although pSrc and pPKB do not become phosphorylated in the majority of HOSCC 
cells in response to ROS stimulation, pGSK3- β may become phosphorylated by two 
pathways: one of which inhibits PKB phosphorylation while the other actives PKB. 
Therefore, the levels of pPKB remain unchanged in WHCO1, WHCO5 and SNO cells while 
the levels of pGSK3- β increase (See Figure 4.1).  
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Figure104.1: Proposed pathway by which the abundances of pSrc and pPKB remain 
unchanged, while that pGSK3-β increases in WHCO1, WHCO5 and SNO cells 
It is proposed that ROS stimulate the MAPK and Wnt pathways in the WHCO1, WHCO5 and SNO 
cell lines. ROS do not appear to activate Src or PKB in these cell lines, however the abundances of 
pGSK3-β increased. It is therefore thought that the MAPK pathway inhibits PKB, while the Wnt 
pathway activates it – resulting in the levels of pPKB being unchanged. On the other hand, both of 
these pathways inhibit GSK3- β by phosphorylating it on the Ser 9 residue. The abundance of 
pGSK3-β thus increases independent of pSrc and pPKB. Green arrows depict an increase in the 
phosphorylation of the respective proteins, while the red arrow indicates inhibition of PKB. 
 
4.2. pSrc plays a PKB-independent role in the activation status of GSK3-β 
The abundance of pSrc did not change significantly in any of the cell lines in response to Src 
inhibition. This was expected due to the nature of the inhibitor, as explained previously. Src 
inhibition did, however, result in a significant decrease in pPKB levels in three of the four 
cell lines that contain detectable levels of pPKB. The abundance of pPKB appeared to 
increase in the H1299 cell line, however this increase was insignificant. The decrease in the 
levels of pPKB in response to Src inhibition confirms that Src does indeed play a role in the 
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activation of PKB in HOSCC cells under standard tissue culture conditions, as the abundance 
of active PKB in these cells decreased significantly when Src was no longer active. 
The significant increase in pGSK3-β in WHCO5 and SNO cells and the insignificant increase 
in WHCO1 cells indicates that the activation status of pGSK3-β is influenced by Src 
inhibition in a PKB-independent manner. This is due to the fact that pGSK3-β is a 
downstream effector of PKB and should thus decrease as the levels of pPKB decrease. 
This again points to the influence of other pathways in the inactivation of GSK3-β in HOSCC 
cells. By inhibiting the activities of pSrc and thus decreasing the abundance of pPKB in these 
three cell lines, other pathways may have been activated in an attempt to avoid apoptosis, as 
pSrc is considered to be pivotal in cell survival. The most likely pathway to be activated is 
again the MAPK pathway, as the p38 MAPK is known to respond to many types of cellular 
stress (Zhang & Liu, 2002). In addition to this, as described previously, the PKB pathway has 
an inhibitory effect on the MAPK pathway. Thus, in the absence of active PKB, the MAPK 
pathway may become hyper-activated. 
The activation of the p38 MAPK via the MAPK pathway should result in an increase in 
pGSK3-β (Zhang & Liu, 2002). This pathway will also activate ERK, which will lead to the 
inactivation of pPKB (Zhang & Liu, 2002). The inhibition of pSrc may have also led to a 
decrease in activity in PI3K and the Wnt pathway, which would further decrease the 
abundance of pPKB within the WHCO1, WHCO5 and SNO cells (See Figure 4.2). 
WHCO6 cells also displayed a significant decrease in pPKB levels in response to Src 
inhibition, however the levels of pGSK3- β did not change significantly. This could be due to 
the inhibition of Fyn by KX01 as the abundance of pGSK3- β was unchanged, whereas a 
decrease was noticed when Fyn was presumably activated by ROS. This highlights the lack 
of symmetry between the levels of pPKB and pGSK3- β in WHCO6 cells and implies that 
GSK3-β is phosphorylated independently of pPKB in this cell line. 
Interestingly, there was an increase in the levels of pPKB and a slight yet significant increase 
in pGSK3-β in H1299 cells in response to Src inhibition. This was unexpected, seeing as 
H1299 cells do not display detectable levels of active Src. There is however a possibility that 
the inhibitor affects the abundance of pSrc at a level below what is detectable by the Western 
blotting technique applied in aid of this study. 
WHCO3 cells displayed a significant decrease in the abundance of pGSK3- β in response to 
Src inhibition. WHCO3s are however known within the laboratory to behave differently to 
the other cell lines, often for reasons that have yet to be discovered (Nerwich, 2013; Shaw, 
2011; Fanucchi, 2011). 
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Figure114.2: Proposed pathway by which the abundance of pGSK3- β increases in response to 
Src inhibition, despite a decrease in pPKB abundance in WHCO1, WHCO5 and SNO cells 
It is proposed that the inactivation of Src incites a stress response in the WHCO1, WHCO5 and SNO 
cells, which leads to the activation of the MAPK pathway. The MAPK pathway has the potential to 
decrease pPKB abundance while increasing pGSK3-β abundance via the p38 MAPK. The lack of Src 
activity may also decrease the activation of PI3K and the Wnt pathway, which will further decrease 
the abundance of pPKB within the cells. Green arrows depict an increase in the phosphorylation of the 
respective proteins, while the red arrow indicates inhibition of PKB. The red cross is indicative of Src 
inhibition. 
 
4.3. pSrc may inhibit pPKB activation in response to oxidative stress 
The levels of pSrc after exposure to oxidative conditions coupled with Src inhibition are not 
dissimilar to those exposed to oxidative conditions only. This underscores the fact that the 
Src inhibitor does not alter the phosphorylation status of Src. However, a slight yet significant 
decrease in pSrc abundance was observed in WHCO5 cells, which displayed an insignificant 
decrease in pSrc levels in response to ROS stimulation only. This indicates that oxidative 
conditions alone may result in a significant decrease in pSrc in WHCO5 cells if the results 
were to be refined.  
Src inhibition under oxidative conditions resulted in an increase in pPKB across all cell lines 
that display detectable levels of pPKB. The increases were significant in the case of WHCO5 
and SNO cells. Although the increase in pPKB abundance in WHOC1 cells remains 
insignificant, there was a visible increase in the levels when compared to those obtained from 
exposure to oxidative stress alone. The same can be said for the A431 cell line.  
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The abundance of pPKB in WHCO5 cells did appear to decrease when compared to ROS 
stimulation only, however the error bar also decreased to the point that difference from the 
control became significant. This implies that the levels of pPKB may in fact be higher in 
response to Src inhibition under oxidative conditions when compared to the response to 
oxidative conditions alone, as the results are far less erratic. The levels of pPKB in WHCO6 
and H1299 cells did not change very much when the Src inhibitor was applied in conjunction 
with the oxidative conditions compared to oxidative conditions alone. However, in SNO 
cells, the difference was visible and significantly higher. 
The results indicate that active Src may actually inhibit the phosphorylation of PKB in 
response to oxidative conditions in WHCO1, WHCO5, SNO and A431 cells. Conversely, 
inactivating Src does not appear to have an effect on the activation status of pPKB in 
WHCO6 and H1299 cells undergoing oxidative stress. The abundance of pGSK3-β in 
WHCO6 cells did, however, increase under oxidative conditions coupled with Src inhibition, 
whereas a decrease was observed under oxidative conditions only. This indicates that Src 
may play a role in the activation (decline in inhibitory phosphorylation) of GSK3-β under 
oxidative conditions in WHCO6 and possibly H1299 cells. This falls in line with the notion 
that Fyn plays a role in GSK3-β activation in these cells because, if Fyn is inhibited by 
KX01, it cannot activate GSK3-β. This will allow pPKB to phosphorylate GSK3- β at Ser9. 
In the case of WHCO1, WHCO5, SNO and perhaps A431 cells, the evidence again points to 
the MAPK pathway. ERK activation, which can inhibit PKB, has been found to be Src-
dependent (Lee, 2006), particularly under oxidative conditions (Aikawa, 1997). Inhibition of 
Src thus allows for the activation of PKB by disabling the activation of ERK. Thus, ROS 
could be activating the MAPK, Wnt and PI3K (through RAS) pathways, which all lead to the 
phosphorylation of PKB and GSK3- β (see Figure 4.3). 
In order to confirm whether these experiments are in fact activating the above-mentioned 
pathways, a reliable way to isolate the Src-PKB-GSK3-β pathway and thus determine the 
effects of ROS on this pathway in a more secluded manner must be found. Because the A431 
skin epidermoid carcinoma cells responded similarly to four of the five HOSCC cell lines 
with respect to Src inhibition under oxidative conditions, it would also be useful to determine 
whether the observed reaction applies to other forms of squamous cell carcinomas. 
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Figure124.3: Proposed mechanism by which pPKB and pGSK3- β become activated in 
WHCO1, WHCO5 and SNO cells responding to Src inhibition under oxidative conditions 
It is proposed that, in the absence of Src, ERK does not become activated under oxidative conditions. 
This allows for the activation of PKB via the MAPK, Wnt and PI3K (via RAS) pathways by ROS. 
These pathways, as well as pPKB, all phosphorylate GSK3- β at the Ser 9 residue. Thus, WHCO1, 
WHCO5 and SNO cells display an increase in the abundance of both pPKB and pGSK3- β in 
response to Src inhibition coupled with ROS stimulation. Green arrows depict an increase in the 
phosphorylation of the respective proteins, while the red arrow indicates inhibition of PKB. The red 
crosses are indicative of inhibition. Src is inhibited by KX-01, while ERK activation under oxidative 
conditions is Src-dependent. 
 
5. Conclusion 
It appears that, in three of the five HOSCC cell lines (WHCO1, WHCO5 and SNO), Src 
inhibits the phosphorylation of PKB, but not GSK3-β, under oxidative conditions. This is 
likely to occur via activation of the MAPK pathway which can play a negative regulatory role 
in the PKB pathway by inhibiting PKB activation (Yu et al., 2002). The MAPK pathway still 
has the capacity to phosphorylate GSK3- β at the Ser 9 residue, even in the absence of pPKB, 
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while other pathways stimulated by ROS, such as the Wnt pathway, can also phosphorylate 
GSK3-β.  
The behaviour of the WHCO6 and WHCO3 cell lines deviates from the pattern observed in 
the other HOSCC cells. It has been shown previously that WHCO3 cells often behave 
differently to the other HOSCC cell lines (Nerwich, 2013; Shaw, 2011; Fanucchi, 2011), 
although the reason for this has yet to be elucidated. The behaviour of WHCO6 cells, 
however, may be explained by the activation of Fyn, a SFK that is also activated by ROS 
stimulation yet plays a role in the activation of pGSK3-β (resulting in a decline in the 
abundance of the Ser 9 phosphorylation). 
The control cell lines A431 and H1299 also behave differently as the reactions of A431 
appeared to be similar to the WHCO1, WHCO5 and SNO cell lines, whereas that of H1299 
was sometimes similar to WHCO6. It is unsurprising that these cell lines behave differently 
as A431 cells were derived from epidermoid carcinoma, while H1299 cells were derived 
from non-small cell lung carcinoma. The alignment of the behaviours of the respective 
HOSCC cell lines with these control cell lines is also not entirely surprising, as they are both 
squamous cell carcinomas. However, the fact that three of the five cell lines behave similarly 
to A431s, one behaves similarly to H1299s, and one does not behave similarly to any of the 
above-mentioned cell lines highlights the differences between HOSCC cell lines derived 
from different patients.  
The differences in these cell lines also emphasises the fact that cross-talk plays a major role 
in the transformation and maintenance of cancer cells. It is clear that further research must be 
undertaken in order to understand the intricacies involved in the cross-talk between the 
MAPK, Src/PKB/GSK3-β and Wnt pathways. The comprehension of these complicated 
pathways is essential for the ultimate treatment of this devastating disease. 
Thus, the need to identify a variety of testable markers for HOSCC is underscored. Although 
the cell lines investigated in this study are all moderately differentiated carcinomas, the path 
to becoming a tumour can vary from person to person. With more testable markers available, 
the treatment of this disease that affects so many South Africans may become easier and 
more successful.  
I believe that inactive Src (phosphorylated at Y527) in HOSCC cells with elevated ROS 
levels could potentially be one of these markers, as Src inhibition under ROS stimulation led 
to an increase in pPKB and a decrease in GSK3-β activation in four out of five HOSCC cell 
lines. This is most noteworthy, as an increase in inactive GSK3-β has been found to 
significantly increase cell growth (Wang et al., 2008), while an increase in pPKB has been 
found to enhance cell proliferation in HOSCCs (Gen et al., 2013). It should also be noted that 
similar behaviour was observed in A431 cells. Thus, inactive Src present in HOSCC cells, 
and possibly other squamous cell carcinomas, undergoing oxidative stress may be a 
contributing factor to the carcinogenesis of these cells. 
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7. Appendices  
 
Appendix A 
 
1. Tissue Culture Solutions 
 
1.1. DMEM medium 
1.37 % Dulbecco‘s Modified Eagle‘s Medium (DMEM) 
0.37 % Sodium bicarbonate 
2 % Penicillin/Streptomycin solution (Penicillin: 500 U/ml; Streptomycin: 0.5 %) 
Made up to final volume with dH2O.  
 
1.2. Ham’s F12 medium 
1.07% Hams F12 medium 
0.118 % Sodium bicarbonate 
2 % Penicillin/Streptomycin solution  
Made up to final volume with dH2O 
 
1.3. Mix  
3 Volumes DMEM medium solutions: 1 volume Hams F12 medium solution  
Filter sterilized  
Stored at 4 oC. 
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1.4. 1 x PBS 
136.9 mM NaCl  
2.86 mM KCL 
10.1 mM Na2HPO4.12H2O 
1.76 mM KH2PO4 
pH adjusted to 7.2-7.3, made up to 1 L with dH2O. 
Solution sterilized for 20 minutes at 1511bq and store at 4 oC 
 
1.5. Trypsin:EDTA solution 
0.02 % EDTA in 500 ml PBS 
0.1 % Trypsin in 1 L PBS 
EDTA:Trypsin mixed (1:1) to obtain a final concentration of 0.01 % EDTA and 0.05 % 
Trypsin  
Stored at 4 oC. 
 
2. Whole cell protein extraction solutions 
 
2.1. 2x Laemmli lysis buffer 
4 % SDS 
20 % Glycerol 
10 % β-mercaptoethanol 
Solution made up to a final volume with 0.0625 M Tris-HCL buffer, pH 6.8.  
 
3. Protein determination solutions 
 
3.1. Coomassie Brilliant Blue Stain 
0.25 % Coomassie blue powder 
50 % Methanol 
10 % Acetic Acid 
Made up to final volume with dH2O. Stored at room temperature 
 
3.2. Destain 
10 % Glacial acetic acid 
12 % Methanol 
Made up to final volume with dH2O 
 
3.3. Elution Solution 
66 % Methanol 
33% dH2O 
1 % Ammonia 
 
4. SDS PAGE solutions 
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4.1. Stacking gel 
5 % acrylamide 
0.1 % NN’-methylenebisacrylamide  
125 mM Tris-HCl, pH 6.8 
0.2 % SDS 
Made up to final volume with dH2O 
1 mM Ammonium persulphate (APS) and 0.25 % N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) added for gel polymerisation 
 
4.2. Separating gel 
10 % acrylamide 
% NN’-methylenebisacrylamide 
375 mM Tris-HCl, pH 8.8 
0.2% SDS 
Made up to final volume with dH2O 
 
4.3. Running Buffer 
3.74 mM SDS 
2.5 mM Tris-HCl pH 8.3 
192.5 mM Glycine 
Made up to final volume with dH2O 
 
4.4. Gel Destain Solution 
10 % Acetic Acid 
10 % Methanol 
Made up to final volume with dH2O 
 
5. Western Blotting Solutions 
 
5.1. Transfer Buffer 
25 mM Tris-HCl, 9H 8.3 
1.41 % Glycine 
20 % Methanol 
Made up to final volume with dH2O 
 
5.2. Tris Buffer Saline  
50 mM Tris-HCl (pH 7.8) 
150 mM NaCl 
2 mM CaCl2.2H2O 
Made up to final volume with dH2O 
 
5.3. Blocking Solution 
5 % Fat Free milk powder 
Made up to final volume with TBS with 0.1 % Tween-20 
50 
 
 
5.4. Developer 
6.4 M Metol 
0.6 M Sodium Sulphite (Anhydrous) 
80 mM Hydroquinine  
0.45 mM Sodium Carbonate (Anhydrous) 
34 mM Potassium Bromide 
Made up to final volume with dH2O. Stored in the dark 
 
5.5. Fixer 
0.8 M Sodium Thiosulphate 
0.2 M Sodium Metasulphite  
Made up to final volume with dH2O. Stored in the dark 
 
Appendix B    
1. Representative standard curve for Protein Determination 
 
Figure13B1: Standard Curve for Protein Determination 
Absorbance readings at 595 nm for 1, 3, 6, 12, 16 and 20 µg BSA. The readings were used to 
construct a standard curve for the determination of protein concentration of various whole 
cell protein extractions. The respective protein concentrations were determined from the 
equation of the standard curve y=0.0135x in this case. The R2 value represents linear 
regression, where a value of 1 represents a perfect fit between the line of best fit and the data. 
 
2. Representation of 10 % SDS PAGE-resolved protein extracts 
y = 0.0135x
R² = 0.9924
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Figure14B2: Resolution of Whole Cell Extracts 
Representative SDS PAGE gel comprised of 10 % acrylamide, prepared according to 
Laemmli (1970). 40 µg of whole cell protein extracts as well as 1 µl of molecular weight 
marker were loaded. The protein samples were separated by applying a constant current of 21 
mA. The gel was stained with Coomassie Brilliant Blue and destained to enable visualisation 
of the bands present on the gel. The gel depicts proteins varying in mass from approximately 
250 kDa to 25 kDa. 
 
3. Antibody dilutions and incubation conditions for Western Blot analysis 
Table B1: Antibody dilutions and incubation conditions 
Primary 
antibody 
Dilution Buffer Secondary 
antibody 
Dilution Buffer and 
temperature 
Actin 1:2 500 2.5 % Fat-
Free milk 
powder in 
PBS 
Goat-anti-
rabbit HRP-
conjugate 
1:10 000 PBS at 30 oC 
in the dark 
 
 
pPKB 1:1 000 5 % BSA in 
TBS-T 
Goat-anti-
rabbit HRP-
conjugate 
1:2 000 5 % milk 
powder in 
TBS-T at 30 
oC in the 
dark 
pSrc 1:1 000 2.5 % BSA 
in TBS-T 
Goat-anti-
rabbit HRP-
conjugate 
1:3 000 2.5 % milk 
powder in 
TBS-T at 30 
oC in the 
dark 
pGSK3-β 1:1 000 2.5 % BSA 
in TBS-T 
Goat-anti-
rabbit HRP-
conjugate 
1:3 000 2.5 % milk 
powder in 
TBS-T at 
room 
temperature 
in the dark 
25 KDa - 
35 KDa - 
55 KDa -  
70 KDa -  
100 KDa -  
130 KDa -  
250 KDa -  
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*All antibodies obtained from Sigma-Aldrich, MO USA 
4. Statistical analyses of data 
Table B2 Statistical analysis of data representing change in pSrc abundance in 
comparison to untreated control in response to ROS stimulation. 
  
Table B3 Statistical analysis of data representing change in pPKB abundance in 
comparison to untreated control in response to ROS stimulation. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
WHCO1 13.935 12.618 No 0.3845 
WHCO3 No detectable expression    
WHCO5 124.190 23.160 No  0.3552 
WHCO6 17.322 1.036 Yes 0.0102 
SNO -1.770 2.874 No 0.5730 
A431 15.526 22.571 No 0.5626 
H1299 6.819 3.263 No 0.1718 
 
Table B4 Statistical analysis of data representing change in pGSK3-β abundance in 
comparison to untreated control in response to ROS stimulation. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
WHCO1 120.88 16.22 Yes  0.0175 
WHCO3 -69.51 0.18 Yes < 0.0001 
WHCO5 37.10 27.83 No 0.2438 
WHCO6 -68.69 17.37 Yes 0.0167 
SNO 44.96 8.125 Yes 0.0311 
A431 -3.11 18.50 No 0.8821 
H1299 13.97 12.04048 No 0.3104 
 
Table B5: Statistical analysis of data representing change in pSrc abundance in 
comparison to untreated control in response to Src inhibition. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
Cell line: Mean – untreated 
control 
SEM Significant P-value 
WHCO1 -22.34 18.383 No 0.3463 
WHCO3 3.56 23.137 No 0.8918 
WHCO5 -11.05 14.799 No 0.4966 
WHCO6 217.68 75.655 Yes 0.0451 
SNO -1.39 11.315 No 0.9081 
A431 9.84 21.946 No 0.6978  
H1299 No detectable expression    
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WHCO1 -18.1171 9.73 No  
WHCO3 5.5 25.062 No 0.891 
WHCO5 -42.05 10.933 No 0.3086 
WHCO6 6.95 16.273 No 0.7430 
SNO 26.80 12.485 No 0.0984 
A431 14.9 15.624 No 0.8475  
H1299 No detectable expression    
 
Table B6: Statistical analysis of data representing change in pPKB abundance in 
comparison to untreated control in response to Src inhibition. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
WHCO1 -13.752 0.10 Yes 0.0048 
WHCO3 No detectable expression    
WHCO5 -26.88 6.46 Yes 0.0141 
WHCO6 -13.13 3.01 Yes 0.0358 
SNO -7.555 7.51 No 0.4342 
A431 2.053 3.08 No 0.8373 
H1299 31.83 9.51 No 0.3854 
 
Table B7: Statistical analysis of data representing change in pGSK3-β abundance in 
comparison to untreated control in response to Src inhibition. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
WHCO1 19.34 17.25 No 0.3789 
WHCO3 -73.60 3.47 Yes 0.0299 
WHCO5 60.60 12.77 Yes 0.0416 
WHCO6 -12.29 13.14 No 0.4026 
SNO 114.12 15.39 Yes 0.0018 
A431 -0.018 16.49 No 0.9992 
H1299 20.64 4.77 Yes 0.0124 
 
Table B8: Statistical analysis of data representing change in pSrc abundance in 
comparison to untreated control in response to Src inhibition under oxidative 
conditions. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
WHCO1 -2.45 16.19 No 0.8937  
WHCO3 -1.89477 0.5442 No 0.0735 
WHCO5 -37.03 5.075 Yes 0.0183 
WHCO6 232.56 42.32 Yes 0.0384 
SNO -7.057 5.79 No 0.2258 
A431 14.88978 21.03805 No 0.5525 
H1299 No detectable expression    
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Table B9: Statistical analysis of data representing change in pPKB abundance in 
comparison to untreated control in response to Src inhibition under oxidative 
conditions. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
WHCO1 28.5914 22.43278 No 0.3305 
WHCO3 No detectable expression    
WHCO5 23.41 2.899 Yes 0.0062 
WHCO6 22 6.956 No 0.0871 
SNO 17.5057 4.528026 Yes 0.0083 
A431 23.16124 9.904842 No 0.5626 
H1299 4.39 17.73 No 0.3418 
 
Table B10: Statistical analysis of data representing change in pGSK3-β abundance in 
comparison to untreated control in response to Src inhibition under oxidative 
conditions. 
Cell line Mean – untreated 
control 
SEM Significant P-value 
WHCO1 70.61 19.48 No 0.0684 
WHCO3 -40.51 1.50 Yes 0.0014 
WHCO5 34.33 6.53 Yes 0.0150 
WHCO6 34.93 7.05 Yes 0.0384 
SNO 42.41 36.03 No 0.3044 
A431 17.74 0.01 Yes > 0.0001 
H1299 51.88 3.43 Yes 0.0001 
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